Posted by on Jan 30, 2018 in Leukemia | 0 comments

In a nutshell

This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant.

Some background

High-risk lymphoma patients with relapsing or unresponsive (refractory) disease may be candidates for allogeneic stem cell transplantation (SCT). This procedure requires a close tissue type match between the donor and the patient, such as a sibling. 

70% of patients don’t have an exact tissue type match. For these patients, haploidentical transplantation can achieve a 50% match. This makes it easier to find donors, helping treat patients more quickly. Stem cells from umbilical cord blood can also be used, but these cells take a long time to restore white blood cell counts. This increases hospitalization time and care costs. Combining these methods could provide the best of both: faster white blood cell recovery with a lower risk of graft-versus-host disease (GVHD, when the transplanted cells attack healthy tissue).

Methods & findings

This study involved 42 patients with a range of lymphomas, both non-Hodgkin’s or Hodgkin’s, or CLL. 29% of patients were in complete remission, while 71% had active disease. 57% of patients were at high or very high risk. 52% of patients had received three or more lines of therapy prior to the transplant procedure.

By 60 days post-transplant, 100% of patients had white blood cell recovery, and 91% of patients had platelet (blood cells involved in clotting) count recovery. 21% of patients developed acute GHVD, with an 8% occurrence of chronic GHVD at 1 year. 28% of patients experienced disease progression or relapse, with a 19.5% occurrence of relapse at 1 year. Overall, CLL and follicular lymphoma (FL) patients had the best outcomes, staying in remission.

At an average follow-up of 42 months, the rate of relapse-free survival (time from treatment until disease return) was 53%. Progression-free survival (time from treatment until disease progression) was 62%, and overall survival (time from treatment until death from any cause) was 65%.

Epstein-Barr virus (EBV) reactivation occurred in 31%. Cytomegalovirus (CMV) reactivation occurred in 36%. Both were easily controlled with treatment. 

The bottom line

This study concluded that combined haploidentical cord transplant provides fast white blood cell recovery and low rates of GVHD, making it a good alternative treatment for patients with high-risk, relapsed, or refractory lymphomas.

The fine print

This study only had 42 patients, which is a very small sample size. T-cell and Hodgkin’s lymphoma represented the two largest groups of patients (31% and 21%), but more studies with larger patient populations are needed for comparison.

What’s next?

If you have relapsed or refractory lymphoma, talk to your care team about a combined haploidentical cord transplant as an alternative treatment option.

Published By :

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Date :

Nov 08, 2017

Original Title :

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and CLL.

click here to get personalized updates